Key result
Value-based insurance and adherence strategies emerge as key targets to improve post-MI outcomes.
Answers are grounded in this paper and cite their sources.
Interventions that both improve outcomes and save costs are unusual, but the provision of lifesaving medications to survivors of myocardial infarction is one such example.1 In the past, physicians' poor compliance with evidence-based guidelines was a major reason for suboptimal use of such medications. Now, with help from the dissemination of quality metrics, cost-saving medications such as beta-blockers, aspirin, and angiotensin-converting–enzyme (ACE) inhibitors are nearly universally prescribed to eligible patients after myocardial infarction,2,3 so the focus has switched from physician prescribing to patient adherence. The concept of value-based insurance design,4 which is encouraged by the Patient Protection and Affordable . . .
No takes yet. Share an insight, caveat, or question.
Goldman et al. (2011) conducted an editorial in Myocardial infarction. Value-based insurance design was evaluated. Value-based insurance design and patient adherence strategies are highlighted as the new focus for improving outcomes in myocardial infarction survivors, given high physician prescribing rates.
Synapse has enriched 10 related papers. Consider them for comparative context: